Dr. Moshim Kukar's team at Roswell Park Comprehensive Cancer Center has performed more than 700 minimally invasive esophagectomies since 2014.

Bayer today announced that the U.S. Food and Drug Administration (FDA) has granted full approval for VITRAKVI® (larotrectinib), a first-in-class TRK inhibitor for the treatment of adult and pediatric ...